Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc.（TARS）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · TARS · 截至 2025年9月30日
股东结构概览
225
机构持有人数
▲ 18 vs Q2
$2.67B
机构持仓总市值
▲ $798.96M vs Q2
43.02M
总流通股
freeFloat 93.82%
44.89M
13F 申报持股数
▼ 1.24M vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
TARS 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
BLACKROCK, INC. biological products, (no diagnostic substances) | 3.78M | 8.92% | 8.92% | $224.62B | Nov 12, 2025 | ▼ 12.6K |
RTW INVESTMENTS, LP biological products, (no diagnostic substances) | 3.18M | 7.50% | 7.50% | $188.84B | Nov 14, 2025 | ▲ 65.8K |
DEEP TRACK CAPITAL, LP biological products, (no diagnostic substances) | 3.00M | 7.08% | 7.08% | $178.29B | Nov 14, 2025 | ▲ 1.25M |
PARADIGM BIOCAPITAL ADVISORS LP biological products, (no diagnostic substances) | 2.67M | 6.29% | 6.29% | $158.42B | Nov 14, 2025 | ▼ 310.4K |
JENNISON ASSOCIATES LLC biological products, (no diagnostic substances) | 2.60M | 6.15% | 6.15% | $154.79B | Oct 30, 2025 | ▲ 136.6K |
TANG CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 2.45M | 5.79% | 5.79% | $145.89B | Nov 14, 2025 | — held |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 2.27M | 5.36% | 5.36% | $135.03B | Nov 7, 2025 | ▼ 25.3K |
MORGAN STANLEY biological products, (no diagnostic substances) | 1.91M | 4.51% | 4.51% | $113.65B | May 27, 2026 | ▼ 143.3K |
JANUS HENDERSON GROUP PLC biological products, (no diagnostic substances) | 1.44M | 3.40% | 3.40% | $85.55B | Nov 14, 2025 | ▼ 367.9K |
ASSENAGON ASSET MANAGEMENT S.A. biological products, (no diagnostic substances) | 1.25M | 2.95% | 2.95% | $74.17B | Oct 7, 2025 | ▲ 250.4K |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
21
增持
+2.65M 股4
新建仓
首次建仓20
减持
−2.17M 股0
清仓
完全退出净股数变化（前50家）
+482.2K
+2.65M / −2.17M
净新增持仓人
+5
新建 4 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
TARS 内幕交易记录
数据来源：SEC Form 4
近期内部人员以卖出为主。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
23
买入笔数
52
卖出笔数
0.44
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Neervannan Seshadri Chief Operating Officer | Mar 20, 2026 | Sale | 2,989 | $66.75 | $199.5K | 82.8K | Form 4 ↗ |
Whitfield Dianne C. Chief Human Resources Officer | Mar 17, 2026 | Sale | 4,029 | $69.42 | $279.7K | 43.3K | Form 4 ↗ |
Whitfield Dianne C. Chief Human Resources Officer | Mar 18, 2026 | Sale | 4,071 | $68.71 | $279.7K | 39.2K | Form 4 ↗ |
Whitfield Dianne C. Chief Human Resources Officer | Mar 19, 2026 | Sale | 4,174 | $67.00 | $279.7K | 35.0K | Form 4 ↗ |
Wahl Bryan General Counsel | Mar 17, 2026 | Sale | 4,084 | $69.42 | $283.5K | 72.3K | Form 4 ↗ |
Wahl Bryan General Counsel | Mar 18, 2026 | Sale | 4,125 | $68.71 | $283.4K | 68.2K | Form 4 ↗ |
Wahl Bryan General Counsel | Mar 19, 2026 | Sale | 4,231 | $67.00 | $283.5K | 64.0K | Form 4 ↗ |
Neervannan Seshadri Chief Operating Officer | Mar 17, 2026 | Sale | 3,125 | $69.42 | $216.9K | 94.0K | Form 4 ↗ |
Neervannan Seshadri Chief Operating Officer | Mar 18, 2026 | Sale | 3,610 | $68.71 | $248.0K | 90.4K | Form 4 ↗ |
Neervannan Seshadri Chief Operating Officer | Mar 19, 2026 | Sale | 4,589 | $67.00 | $307.5K | 85.8K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Tarsus Pharmaceuticals, Inc.（TARS）主要由机构投资者持有，机构持股比例约为 100.0%。公司内部人员持股约 6.18%，散户及公众持股约占剩余的 0.00%。
Tarsus Pharmaceuticals, Inc. 最大机构股东为 BLACKROCK, INC.，截至 September 30, 2025 持有约 3.78 million 股，占总流通股的 8.92%。
目前共有 225 家机构持有 TARS 股票，合计持仓市值约 $2.67 billion，数据来源为最新 SEC 13F 申报。
常见问题
TARS ownershipTarsus Pharmaceuticals, Inc.（TARS）主要由机构投资者持有，机构持股约 100.0%。最大股东为 BLACKROCK, INC.，持股比例 8.92%。内部人员持股约 6.18%。数据来源 SEC Form 13F，截至 September 30, 2025。